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Summary points
• Regulatory approval of new tuberculosis (TB) drugs can be based on data from trial(s)
using a surrogate endpoint of treatment efficacy under an accelerated or conditional
procedure. In such circumstances, policy makers and TB programs can be hampered in
their ability to make recommendations on the optimal use of the drug(s), and conse-
quently, the uptake by national or international public health institutions of such rec-
ommendations can be limited.
• Based on the essential need to produce high-quality evidence for policy decisions, this
paper reflects on specific methodological issues in clinical trial design that need to be
addressed to improve compliance with clinical, regulatory, and public health requirements.
• Established mechanisms for communication between drug developers and regulators
already exist; however, equal engagement with policy makers is also essential for the
optimal selection of trial designs, endpoints, and markers of treatment outcome and for
giving consideration to public health and program aspects.
• The next generation of TB trials should better reconcile the research agenda with the
need for global policies on access to TB medicines. Policy decision-makers should estab-
lish formal mechanisms for iterative feedback on regimen-development pathways. In
this paper, we provide examples of how the need for interactions between regulators, tri-
alists, and policy decision-makers can be addressed.
Introduction
Under the paradigm of adding a new drug to a regimen or substituting single drugs in a regi-
men one at a time, it would take 15–20 years to develop an entirely new tuberculosis (TB) regi-
men comprising three to four new drugs [1]. As has been noted in the papers of this Special
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Collection on Advances in Clinical Trial Design for Development of New TB Treatments [2–
4], the major challenges in the development of new TB treatments include the long develop-
mental pathway to identify best regimens, the uncertainties around the correlation between
the treatment effect and existing surrogate endpoints, and uncertainties around the predictive
quantitative relationships between Phase II and Phase III trial outcomes. Beyond measures of
efficacy, the development of shorter, simpler regimens combining new and existing drugs also
requires detailed information on their respective safety and toxicity, their potential for drug–
drug interactions, their propensity for development of drug resistance while on therapy, and
their use in specific patient populations such as persons infected with human immunodefi-
ciency virus (HIV), pregnant women, and children [5].
Over the last decade, a series of clinical trials have been carried out to assess the safety and
efficacy of new or repurposed drugs for the treatment of TB [6]. Although in some of these tri-
als the endpoints were selected to address regulatory requirements, such endpoints were not
always optimal to draw inferences for policy-recommending institutions, such as the World
Health Organization (WHO), that provide guidance on the optimal use of these drugs in com-
bination treatment regimens [2]. Ideally, clinical trials should provide results that are as mean-
ingful as possible for clinical, regulatory, and programmatic perspectives. In situations when
the regulatory approvals are conditional, based on surrogacy or on preliminary limited clinical
data sets, the question is posed as to what extent policy makers can suitably generate compre-
hensive recommendations on the optimal use of the drug(s) in combination regimens. What
needs to be considered in the design of a clinical trial to have relevance across regulatory and
programmatic requirements? The design and choice of specific endpoints in trials of new TB
drugs and regimens have implications for the development of guidelines and their adoption by
national or international public health institutions. Starting from the need to produce evidence
of high quality, this paper reflects on study designs and endpoints that respond best to the
combined clinical, regulatory, and public health requirements.
The regulatory needs
In principle, regulatory authorities overseeing drug development have the primary responsibil-
ity of ensuring that the quality, efficacy, and safety of marketed medicinal products are ade-
quate, conforming to currently defined standards. A key role of the regulatory authorities is to
determine whether there is a positive benefit–risk balance to support use of the drug for the
proposed indication and patient population.
Regulators also continue to reevaluate the benefit–risk balance after approval through phar-
macovigilance activities and postmarketing studies. New data that emerge in the postapproval
phase are taken into consideration in reassessing the benefit–risk balance, and information is
communicated in product labeling as appropriate. Regulators, however, are not expected to
consider cost-effectiveness or to perform in-depth evaluations of comparative effectiveness in
assessing benefit and risk or for defining treatment policies. This role lies, rather, within the
scope of public health recommending bodies, and, even if at times there seems to be some
overlap, it is important to recognize and understand the implications of this distinction.
Some regulatory agencies have mechanisms for accelerated reviews and early approval of
new drugs that address unmet needs according to specified criteria—e.g., the conditional mar-
keting authorization pathway in the European Union where the benefit–risk balance of the
new drug is such that immediate availability justifies acceptance of less comprehensive data
than normally required [7, 8]. In the United States, the accelerated approval pathway allows
for the approval of a product for a serious disease with an unmet need based on a surrogate or
an intermediate clinical endpoint that is reasonably likely to predict clinical benefit [9]. The
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accelerated approval pathway has been used primarily in conditions in which the disease
course is long and an extended period of time would be required to measure the intended clin-
ical benefit of a drug. The implication is that, while awaiting further data to be generated post-
approval, there may be limited data to support policy recommendations at this stage.
Development of new TB drugs and regimens is a good example of a scenario in which regu-
lators need to establish that a drug submitted for licensure is safe and effective for the proposed
use, whereas recommending bodies need to define how to use the drug optimally within a regi-
men in a way that addresses the public health need. Often, demonstrating the safety and effec-
tiveness of a drug is the first step. Although a single clinical study cannot answer all research
questions at once, it is still worth exploring clinical study designs that maximize the chance of
gathering evidence that is informative both for assessing the benefit–risk of individual drugs
and for determining their optimal use in the context of TB regimens. In view of the shift in
focus toward the development of new treatment regimens, the European Medicine Agency
(EMA) has proactively issued updated guidance to developers to address such scenarios [10].
In July 2017, the US Food and Drug Administration (FDA) held a public workshop regarding
scientific and clinical trial design considerations for development of new TB drug regimens
[11]. Of note, the FDA and EMA work collaboratively to provide advice to pharmaceutical
sponsors or investigators on various aspects of the clinical trial design and to ensure that,
whenever feasible, the same development program addresses the regulatory requirements of
these agencies (for instance, the FDA pre–investigational new drug (IND) consultative process
allows facilitated early communications between the FDA and potential drug sponsors or
investigators [12]).
The public health needs
Countries, technical agencies, donors, and other TB stakeholders, routinely seek guidance and
advice from WHO on optimal disease management practices to be adopted based on the evi-
dence available. Over the last decade, WHO has published a series of normative guidance doc-
uments for the diagnosis and treatment of all forms of TB, with a particular focus on the needs
of low- and middle-income countries [13]. In 2007, WHO adopted a procedure to guarantee
that guidelines are based on the best available evidence and meet the highest international
standards. Using the Grading of Recommendations Assessment, Development, and Evaluation
(GRADE) framework, which relies on the use of systematic reviews and meta-analyses, the
findings of these reviews are then considered in the context of implementation and feasibility
issues of stakeholder countries [14, 15]. The GRADE framework provides an explicit and
transparent approach to assess the level of certainty in the evidence across relevant studies and
outcomes and to translate that evidence to recommendations. This framework incorporates
multiple processes to minimize bias and optimize usability and requires rigor, fairness, and
transparency in all judgments and decision-making.
To formulate evidence-based recommendations, four key aspects are taken into account:
(1) the respective magnitude of benefits and harm conferred by the intervention under evalua-
tion; (2) the consideration of resource use, feasibility, acceptability, and equity; (3) the cer-
tainty (“quality”) of evidence; and (4) patients’ values and preferences. Based on this
assessment, the proposed recommendation is qualified as “strong” or “conditional” (i.e.,
“weak”), reflecting the extent to which one can, across the range of patients for whom the rec-
ommendation is intended, be certain in the evidence that the desirable effects of the given
intervention outweigh the undesirable effects. The assessment of each of the above aspects
leads, understandably, to the consideration of a number of nuances when moving from clinical
trial results to public health policy making. As a result, the final qualification of the
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recommendation ultimately has implications for the way policy makers, clinicians, and
patients interpret and adopt the guidance, as shown in Table 1.
Recent developments highlight how trial results that are used as the basis for regulatory
approval may allow only conditional recommendations for policy making due to the use of
surrogate endpoints and limited data on patient- and population-relevant outcomes. As an
example, the accelerated approval of bedaquiline by the US FDA in December 2012, based on
the surrogate endpoint of sputum culture conversion at 6 months, allowed the drug to be read-
ily used in the treatment of multidrug-resistant (MDR)-TB under certain conditions in the
field [16]. However, the data gathered from the pivotal Phase II trial appeared inadequate for
policy decision-making because of the absence of information on the outcomes of interest
(nonrelapsing cure); further, the selected design did not provide information on the optimal
use of the drug in combination with others or whether the addition of the drug would allow
any modification in treatment duration. Finally, there was an excess of deaths in the experi-
mental arm, the significance of which was uncertain given the small sample sizes and lack of
long-term follow-up. These limitations in the available evidence at the time of regulatory
review led to the adoption of a conditional recommendation that had implications in terms of
wider scale-up of the intervention. Thus, for bedaquiline, results of the pivotal Phase II trial, in
addition to relevant safety data, were adequate for obtaining regulatory approval but appeared
insufficient for wider policy recommendations [17], thus calling for postlicensure evidence
generation. The yield of a large body of observational data obtained over a subsequent period,
associated with large individual-patient data meta-analyses, allowed WHO to update its rec-
ommendations for MDR-TB treatment in December 2018 [18], with significant changes in the
assessment of the quality of evidence. As a result, bedaquiline is now strongly recommended
for use in the treatment of MDR-TB, based on moderate-quality evidence—showing the
importance of collecting additional data to complement early trial results. It should be noted
that, at the time, the standard of care for rifampicin-resistant (RR)-TB treatment had low effi-
cacy and high toxicity and was based on observational evidence. Though these conditions are
now changing, a similar situation may present itself again in the future. Therefore, the experi-
ence with bedaquiline raises the question of whether specific trial features and designs can be
used to produce endpoints with value for both the regulator and the policy maker. It is with
this objective in mind that the Task Force on New Drug Policy Development established by
WHO in 2012 worked together with drug developers, regulators, scientists, and program man-
agers to define the policy needs and produce relevant documents [19].
Methodological issues: How to fit both regulatory and
programmatic decision-making needs
Could outcome definitions in clinical trials be redesigned to satisfy both regulatory and pro-
grammatic decision-making needs? We argue that this is feasible, and WHO Technical
Table 1. Implications of GRADE recommendations.
Target
population
Strong recommendation Conditional/weak recommendation
Policy makers The recommendation can be adapted as a policy in most situations There is a need for substantial debate and involvement of stakeholders
Patient Most people in this situation would want the recommended course
of action, and only a small proportion would not
The majority of people in this situation would want the recommended course
of action, but many would not
Clinician Most patients should receive the recommended course of action Be more prepared to help patients to make a decision that is consistent with
their own values/decision aids and shared decision-making
Abbreviation: GRADE, Grading of Recommendations Assessment, Development, and Evaluation
https://doi.org/10.1371/journal.pmed.1002915.t001
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Consultation on Advances in Clinical Trials Design for TB Treatment Regimen proposed fea-
tures and designs that could address this need in greater detail and that are described in rele-
vant papers of this Collection [2, 20].
Regulatory agencies rightfully seek to use conservative approaches to endpoint evaluation,
relying upon the protection from bias provided by randomization. For certain diseases, includ-
ing MDR-TB, the expedited approval pathway can be used based on a surrogate or an interme-
diate clinical endpoint that is reasonably likely to predict a clinical benefit. These endpoints,
however, are not fit-for-purpose for programmatic and policy needs. Whereas intensive efforts
are underway to identify improved intermediate surrogate markers of treatment outcome with
the ability to measure and describe accurately the effect an experimental regimen will likely
have on achieving nonrelapsing cure [21, 22], no marker has yet been identified that fully
serves the needs of TB investigators and regulators, let alone policy makers [23]. The desire for
an equivalent to the viral load in HIV and viral hepatitis trials has been often voiced but not
yet attained, and current efforts are directed toward identification of markers that might reli-
ably predict efficacy. In addition, combination of bacterial (e.g., minimum inhibitory concen-
tration [MIC]) and host (e.g., pharmacokinetic characteristics, adherence, and perhaps genetic
or other features) factors would be of value in dose selection and for predicting outcome [24,
25]. Relevant surrogate markers providing highly reliable estimates of treatment outcome,
once realized, could provide sufficient evidence for guideline development beyond market
approval [4], but until then, the TB therapeutics field has to look to novel trial designs, long-
term endpoint definitions, and other trial features as a means to generating data pertinent to
policy decisions [3].
The “composite” clinical trial endpoint (comprising multiple events such as a combination
of failure, relapse, and death) has been used as a mechanism to capture multiple serious out-
comes of interest with a programmatic perspective, often allowing for smaller sample sizes.
The use of composite endpoints, however, poses some problems, the most significant being
that respective endpoints are of differing individual and public health value (i.e., death is
always a worse outcome than any other). Further, there are often varying levels of certainty
around different endpoints (for example, cause of death is often uncertain in trials performed
in low-resource settings). The choice of the components of a composite endpoint should be
made carefully: because the occurrence of any one of the individual components is considered
to be an endpoint event, each of the components is of equal importance in the analysis of the
composite [26]. For these reasons, when composite outcomes are used, it is essential that infor-
mation on all their components be collected in such a way that they can be disaggregated and
individually reported. As an illustration, endpoints of currently conducted Phase II and Phase
III trials of TB drugs or regimens are shown in Table 2.
Noninferiority (NI) design has become the design of choice in most Phase II and Phase III
trials of new TB drugs and regimens over the last decade, either because of the high efficacy of
the control regimens (as in drug-susceptible TB) or because of the interest in shortening treat-
ment (as in the case of DR-TB). NI trial designs, however, pose a number of methodological
questions, particularly in terms of analysis [27]. In NI trial designs, different analysis popula-
tions are of interest—the effect in all randomized patients and the effect in those who can
adhere to treatment, which have historically been estimated using the intention-to-treat (ITT)
and the per protocol (PP) populations, respectively [28]. The ITT principle allows virtually all
patients to contribute information to the primary trial analysis. In this approach, all random-
ized patients are included in the analysis of results, and favorable status is assigned only to
those patients whose favorable outcome is documented; all others are deemed unfavorable or
nonassessable (including those lost to follow-up, those whose therapy is altered, those who die
or withdraw early, etc.). The PP population, conversely, is composed of those randomized and
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Table 2. Recent and current Phase II and Phase III trials of new TB drugs or regimens, with their respective endpoints. (Trial names shown with a blue background
involve DS TB; those with a gray background involve DR-TB).
Phase II trials
Trial name (registration
no.)
Phase Sample
size
Study groups; +/− dates; locations; sponsor Primary efficacy endpoint (per online registration)
APT (NCT02256696) 2B 183 2 months Pret + RHZ daily and 1 month, Pret + RH
daily, or 2 months Pret + Rifabutin + H + Z daily, and
1 month Pret + Rifabutin + H daily, versus 2 months
HRZE daily, and 1 month HR daily
Opened April 2015 (paused October 2016–May 2017),
results expected 2020.
John Hopkins University, University of Cape Town
Lung Institute
• Time to SCC in liquid medium (�12 weeks);
• Grade� 3 AEs
HIGHRIF-1 Extension 2 30 HIV–
adult
EBA safety, tolerability, PK study
Opened September 2017, results mid-2018; PanACEA
• Rate and severity of AE with increasing doses of
rifampicin up to 50 mg/kg given as single drug or with
HEZ
Janssen C211
(NCT02354014)
2 60 (ped) PK, safety, dose-range 6 months Bdq (daily for 2
weeks, then 3 times a week) plus OBR, single-arm
study
Opened May 2016, results March 2021; India,
Philippines, Russia, South Africa; Janssen
•Number with AE or SAE;
• PK parameters
NC-005 (NCT02193776) 2B 60 Serial sputum culture counts: 8 weeks Bdq (200 mg
daily) + Pret (200 mg daily) + M + Z, single-arm study
with long follow-up
Opened November 2014, preliminary findings
presented at CROI, 2017 (#724LB), final results
expected 2019; TB Alliance
• Bactericidal activity as determined by the rate of change
in time to sputum culture positivity or by TTP in MGIT
OPTI-Q (NCT01918397) 2 100 6 months Lfx (14, 17, or 20 mg/kg/day) plus OBR
versus 6 months Lfx (11 mg/kg/day) plus OBR
Opened January 2015, results expected end 2019;
South Africa, Peru.
NIAID, Boston University, CDC TBTC
• Time to SCC from positive to negative for
Mycobacterium tuberculosis growth on solid medium
Stage 2 STEP 2C 600 HIV
− adults
4 months R (high dose)+H+Z+E, 4 months R (high
dose)+H+Z (high dose)+E, 3 months sutezolid
(optimal dose)+Bdq+Del+M versus 2HRZE/4HR.
Adaptive trial design, examining new treatment
backbones; PanACEA
• This trial will be informed by findings of a Phase II
study to be carried out in drug-sensitive TB patients, the
SUDOCU trial (NCT0395966). This is a dose range study
of sutezolid (0 mg qd, 600 mg qd, 1200 mg qd, 600 mg
bid, or 800 mg bid), all for 3 months combined with 3
months of daily Bdq, Del and M. N = 75.
Phase II/III trials
Trial name (registration
no.)
Phase Sample
size
Study groups; +/− dates; locations; sponsor Primary efficacy endpoint (per online registration)
NC-008 SimpliciTB (DS)
(NCT03338621)
2C/3 300 4 months Bdq + Pret + M + Z versus standard
6-month therapy
Opened August 2018, results expected 2022; TB
Alliance
•Time to culture negative over 8 weeks
(secondary outcome = bacteriologic failure/relapse, or
clinical failure, at 52 and 104 weeks from start of therapy)
NC-008 SimpliciTB (DR)
(NCT03338621)
2C/3 150 4 months Bdq + Pret + M + Z, single-arm study
Opened August 2018, results expected March 2022;
TB Alliance
•Time to culture negative over 8 weeks
(secondary outcome = bacteriologic failure/relapse, or
clinical failure, at 52 and 104 weeks from start of therapy)
NExT (NCT02454205) 2/3 300 6–9 months Bdq + Lzd + Lfx + Z, and either high-
dose H or ethionamide or terizidone daily (all oral)
versus 6–8 months kanamycin + M + Z
+ ethionamide + terizidone daily, then 16–18 months
MZEthTer
Opened October 2015, results expected 2019;
University of Cape Town
• Treatment success, defined as the sum of cured and
treatment-completed cases (standard arm), without
relapse, reinfection, or death during the 15–18 month
follow-up period (test arm)
TB-PRACTECAL
(NCT02589782)
2/3 630 6 months Bdq + Pret + M + Lzd daily, or 6 months
Bdq + Pret + Lzd + Cfz daily, or 6 months Bdq + Pret
+ Lzd daily (all oral) versus local regimen
Opened January 2017, results March 2021; Belarus,
South Africa, Uzbekistan; MSF
Percent with culture conversion in liquid media at 8
weeks; percent unfavorable at 72 weeks (failure, death,
recurrence, loss to follow-up)
(Continued)
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Table 2. (Continued)
TRUNCATE-TB
(NCT03474198)
2/3 900 2 months various new regimens versus standard 6
months; regimens including H + R35 + Z + E + Lzd,
H + R35 + Z + E + Cfz, H + Z + Rpt + Lzd + Lfx, H
+ Z + E + Lzd + Bdq
Opened late 2017, results expected 2021; MAMS
adaptive trial design.
Thailand, Indonesia, Philippines, Singapore; BMRC,
NUS
• Unsatisfactory clinical outcome at week 96 after
randomization (active TB, TB treatment, or death)
MDR-END
(NCT02619994)
2 238 9 or 12 months Del + Lfx (750 or 1,000 mg) + Lzd
(600 mg daily for 2 months, 300 mg daily thereafter)
+ Z, versus local regimen
Opened January 2016, results December 2019; Korea
• Treatment success 24 months after start of treatment
(both “cured” and “treatment completed”)
Phase III trials
Trial name (registration
no.)
Phase Sample
size
Study groups; +/− dates; locations; sponsor Primary efficacy endpoint (per online registration)
endTB (NCT02754765) 3 324 9 months Bdq + Lzd + M + Z daily, 9 months Bdq
+ Lzd + Cfz + Lfx + Z daily, 9 months Bdq + Lzd
+ Del + Lfx + Z, 9 months Del + Lzd + Cfz + Lfx + Z,
or 9 months Del + Cfz + M + Z, versus local regimen
Opened December 2016, results September 2020;
Georgia, Kazakhstan, Kyrgyzstan, Lesotho, Peru;
MSF, Partners in Health
• Proportion favorable at week 73 (not
unfavorable, and culture negative at week 65–73, or
earlier negative culture and no other evidence of
unfavorable)
• In addition, a companion phase 3 trial will be launched
in drug-resistant TB patients, the "end TB-Q" trial
(NCT03896685). This trial compares 6 months or 10
months of daily Bdq, Del, Lzd and Cfz versus WHO
standard of care in DR patients with fluoroquinolone
resistance.
Otsuka Trial 213
(NCT01424670)
3 511 2 months Del (100 mg twice daily) and 4 months Del
(200 mg daily) plus OBR versus 6 months placebo
plus OBR
Opened September 2011, completed June 2016,
preliminary findings presented at IUATLD October
2017, results published 2019; Otsuka
• Time to SCC, i.e., distribution of the time to SCC
during the 6 months of study drug treatment
NC-006 STAND-DS
(NCT02342886)
3 271 (orig
1,200)
4 months Pret (100 mg twice daily or 200 mg once
daily) + M + Z daily, or 6 months Pret (100 mg twice
daily) + M + Z daily, or 6 months Pret (200 mg once
daily) + M + Z daily, versus standard 6-month therapy
Opened February 2015, paused October 2016–May
2017; accrual not resumed; TB Alliance
•Incidence of combined bacteriologic failure or relapse,
or clinical failure, at 12 months from start of therapy
NC-006 STAND-DR
(NCT02342886)
3 13 (orig 300) 6 months Pret (200 mg) + M + Z daily, single-arm
study
Opened February 2015, paused October 2016–May
2017, accrual not resumed;
TB Alliance
•Incidence of combined bacteriologic failure or relapse,
or clinical failure, at 12 months from start of therapy
NiX-TB (NCT02333799) 3 109 (orig
300)
6 months Bdq (200 mg daily for 2 weeks and then 200
mg three times weekly) + Pret (200 mg daily) + Lzd
(600 mg twice daily), single-arm study
Opened March 2015, preliminary findings presented
at CROI, 2017, accrual closed November 2017, with
opening of NC-007 ZeNiX trial; TB Alliance
• Incidence of bacteriologic failure or relapse or clinical
failure through follow-up until 6 months after the end of
(6–9 months) treatment
NC-007 ZeNiX
(NCT03086486)
3 180 2 or 6 months Lzd (600 or 1,200 mg daily, double-
blind) + Bdq (200 mg daily for 2 weeks, then 100 mg
daily) + Pret (200mg daily)
Opened November, 2017, results January, 2021; TB
Alliance
•Incidence of bacteriologic failure or relapse or clinical
failure through follow-up until 26 weeks after the end of
treatment; culture conversion requires at least two
consecutive culture negative/positive samples at least 7
days apart
RIFASHORT
(NCT02581527)
3 800 2 months H + R (1,200 or 1,800 mg) + Z + E daily and
2 months H + R (1,200 or 1,800 mg) daily, versus
standard 6-month therapy
Opened February, 2017, results expected January,
2020; St George’s London, INTERTB
•Combined rate of failure and relapse 12 months after
end of treatment in mITT
• Grade 3–4 AEs
(Continued)
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otherwise eligible participants who complete the trial without significant deviation from the
intended trial behavior; in particular, such participants typically satisfy minimal requirements
for adherence to the trial interventions. Analysis with each of these two populations should
lead to similar conclusions for a robust interpretation [29]. The ICH E9 Guideline further
specifies that “any differences between them can be the subject of explicit discussion and inter-
pretation" [30]. This concern arises in part from the recognition that adherent participants dif-
fer in unknown ways from those who are not adherent, as they may have more favorable
outcomes, no matter what their randomized therapy [31]. The analyses of these trials are most
robust when there is a high level of adherence, as inadequate therapy in all trial arms may lead
to equally poor performance across arms and nonadherers are imputed as treatment failures in
the analysis of all randomized patients, risking creating a false conclusion of NI. Consequently,
it is extremely important that trial protocols encourage a high level of adherence.
Finally, the generalizability of findings from preapproval clinical trials to the different popu-
lations and areas of interest to policy makers is also a significant concern. Some populations
Table 2. (Continued)
SHINE (ISRCTN63579542) 3 1,200 (ped
minimal
disease)
2 months H + R (600 mg) + Z + (in some) E daily, and
Z, and (in some) E daily, and 2 months H + R (600
mg) daily versus standard 6-month therapy
Opened third quarter of 2016, results 2020; treatment-
shortening strategy trial for children with minimal
TB; India, Uganda, South Africa, Zambia; BMRC
• Unfavorable outcome (failure, relapse, death)
• Grade 3–4 AEs
STREAM Stage-1
(ISRCTN78372190)
3 424 4 months daily M + Cfz + Z + E + high-dose H
+ kanamycin (daily for 3 months and then 3 times per
week) + prothionamide, and 5 months of M + Cfz + Z
+ E daily, versus local standard
Opened 2012, closed to accrual June 2015,
preliminary findings presented at IUATLD October
2017, results early 2019; IUATLD, MRC, USAID
• Proportion of patients with a favorable outcome 132
weeks after randomization having not previously had an
unfavorable outcome or been retreated
STREAM Stage-2
(NCT02409290,
ISRCTN18148631)
3 1,155 9 months M + Cfz + E + Z daily, with initial 2 months
of high-dose H + kanamycin + prothionamide daily,
or 9 months Bdq + Cfz + E + Lfx + Z daily, with initial
2 months high-dose H + prothionamide daily (all
oral), or 6 months Bdq + Cfz + Lfx + Z daily with
initial 2 months high-dose H and kanamycin versus
20–24 month local regimen
Opened April 2016, results expected April 2021;
IUATLD, MRC, USAID, TB Alliance
• Proportion of patients with a favorable outcome at week
76 (noninferiority margin 10%)
TBTC 31/A5349
(NCT02410772)
3 2,500 2 months H + Rpt (1,200 mg) + Z + E daily, and 2
months H + Rpt (1,200 mg) daily, or 2 months H
+ Rpt (1,200 mg) + Z + M daily, and 2 months H
+ Rpt (1,200 mg) + M daily versus standard 6-month
therapy
Opened January 2016; results 2020; substudies include
interactions of Rpt and efavirenz, intensive PK and
pharmacodynamics of Rpt, and sputum biomarkers to
predict outcomes; CDC TBTC, ACTG
•TB disease-free survival at 12 months after assignment
•Proportion of participants with grade 3–5 AEs during
treatment
Adapted from Tiberi and colleagues [6].
Abbreviations: AE, adverse event; Bdq, bedaquiline; BMRC, British Medical Research Council; Cfz, clofazimine; CDC, Centers for Disease Control; CROI, Conference
on Retroviruses and Opportunistic Infections; Del, delamanid; DS, drug-sensitive; DR, drug-resistant; E, ethambutol; EBA, early bactericidal activity; H, isoniazid; HIV,
human immunodeficiency virus; IUATLD, International Union Against Tuberculosis and Lung Diseases; Lzd, linezolid; Lfx, levofloxacin; MGIT, mycobacterial growth
in-tube; MSF, Me´decins Sans Frontiers; M, moxifloxacin; mITT, modified intent-to-treat; NCT, identifying registration number on www.ClinicalTrials.gov; NIAID,
National Institute of Allergy and Infectious Diseases; NUS, National University of Singapore; OBR, optimized background regimen; orig, originally; ped, pediatric; PK,
pharmacokinetics; Pret, pretomanid; R, rifampin 10 mg/kg; R35, rifampin at 35 mg/kg; Rpt, rifapentine; SCC, sputum culture conversion; TB, tuberculosis; TBTC, TB
Trials Consortium; TTP, time to positivity; USAID, US Development Aid Agency; Z, pyrazinamide.
https://doi.org/10.1371/journal.pmed.1002915.t002
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may be underrepresented in clinical trials conducted for approvals (e.g., children, elderly peo-
ple, pregnant women, persons with advanced comorbid illness), whereas others are excluded
for reasons of feasibility (e.g., those living far away from a clinic or deemed unreliable for fol-
low-up). Significant problems have arisen from the assumption of generalizability [32]. When
a successful trial establishes the efficacy of a new agent or regimen, efforts are then needed to
expand exploration of the regimens in broader populations, or through additional pragmatic
trials, such as the endTB trial [33]. The need for such trials is unlikely to be addressed through
any innovations in design, but the rationale for excluding special populations even from early
and middle phases of development is currently being revisited in the TB therapeutics field [2,
3, 20].
The link between registration and public health recommendations:
Implications for national TB programs and the way forward
For TB program managers and policy makers at the country level, the successful registration of
a candidate drug is only one component of the decision-making process around adoption and
use. Feasibility, acceptability, resource use, equity, and quality of life are also considered when
formulating public health recommendations, and these rely on qualitative data that need to be
collected in parallel to quantitative assessment of evidence.
WHO guidelines are key for the development of national policies for the care of TB
patients. However, when reliable data are lacking, recommendations are predominantly based
on low or very low certainty in the evidence, which creates challenges for the potential rapid
adoption, successful implementation, and subsequent uptake of the new therapies—as has
been the case with the treatment of DR-TB [34, 35]. Moreover, recommendations, even if
based on low or very low certainty in the evidence, will often create the perception of a new
“standard of care” that subsequently complicates the ability to fund and conduct pragmatic tri-
als that would address the uncertainty left by the lack of data. Policy makers, donors, and ethi-
cal review bodies should be aware that significant uncertainty persists when recommendations
based on very low or low certainty are adopted and that further research is essential to test the
merits of the new standard of care proposed. Such additional research can generate postlicen-
sure data that are important for the update of policies, as in the case of the recent WHO
DR-TB treatment guidelines [18, 36] (Table 3).
Drug and regimen developers already have formal mechanisms of communication with
regulators, but the engagement of policy recommendation institutions should be actively
encouraged and pursued as early as possible at design stages. One example of the value of such
communication relates to the definition of outcomes selected for trials. Discussions with regu-
latory authorities usually identify endpoints that address foundations of efficacy, safety, and
tolerability in studies with shorter follow-up duration; however, these outcomes may not pro-
vide adequate information for guideline developers and policy makers to endorse a given drug
for use in regimens. Integration of long-term outcomes into TB trials as much as is feasible,
along with the standardization of outcomes, should be a top priority for the TB therapeutics
field, using, for example, the novel Phase IIC design, wherein follow-up is extended and the
experimental regimens are used for their intended total duration [37].
Finally, standardized data collection and outcome definitions compatible with the Clinical
Data Interchange Standards Consortium (CDISC) platforms are required by regulatory bodies.
These have enhanced the ability to optimally use GRADE-based methodological approaches to
evaluating the evidence, and should be similarly considered by policy makers. The application
of such data standards to cohorts and the collection of national TB program data would be an
invaluable step forward by allowing real-world data analyses that will greatly inform policy
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decisions. Until then, TB clinical trialists and regimen developers are strongly encouraged to
share individual patient–level data with policy makers to permit meta-analytic data synthesis
approaches to be used in the GRADE methodology [38]. Data sharing in the domain of TB is a
matter of global public good, and funders, donors, and implementers of trials should not only
mandate such expectations for their clinical trials but also allocate funding to support the care-
ful curation of data accessible to the public and to policy makers for future analyses.
Table 3. The interplay between trials and guidelines: Review of the proposals arising from WHO Technical Consultation on Advances in clinical trial design for
development of new TB treatments (adapted from WHO [20]).
Issue Expert consensus To be explored Research gaps
What clinical trial outcomes are
required to inform regulatory and
programmatic decision-making and
need to be prioritized for prospective
implementation in novel trial designs?
A single clinical trial cannot address all
relevant regulatory and policy/public
health questions.
Explanatory trials, novel adaptive trials,
pivotal trials for licensure need to be
followed up with pragmatic trials to
understand the optimal use of new drugs
and regimens.
Consider postauthorization studies to
answer some of the questions that cannot
be addressed in the registrational trial(s)
to help bridge gaps in knowledge.
Treatment success outcomes in
recent trials of MDR-TB were much
higher than that reported in prior
trials and across program settings.
Further research is needed to better
understand the performance of the
standard of care for rifampicin-
susceptible and rifampicin-resistant
TB in various conditions and settings
to aid in the design of future studies.
How can current/novel clinical trial
endpoints that are intended to support
regulatory decisions be subsequently
translated to support programmatic
implementation?
Operational research can help to translate
clinical trial outcomes into WHO
guidance and add evidence for better
programmatic implementation.
Often, patients enrolled in trials are not
reflective of the general population;
consider ways to make trial population
more reflective of the population of
patients who will be receiving treatment
in real life. Also consider pragmatic
studies for better evidence on
programmatic implementation.
Should the assessment of clinical trial
outcomes be updated for harmonization
across regulatory and programmatic
objectives, and if yes, how?
Communication between drug/regimen
developers, regulators, and
recommendation bodies is essential and
should be encouraged and facilitated as
early as possible at design stages.
Approaches to collecting clinical
outcomes data that can potentially
address assessment of safety and efficacy
of the product and answer questions that
are important from a programmatic
perspective should address the following:
• secondary/exploratory analyses are an
option—but caution in overinterpreting
the data
• sample size implications if multiple
primary analyses considered
• importance of prespecifying analyses;
consistent definitions across different
trials are needed; limitations of using
surrogate endpoints (e.g., 2-month
culture conversion) for development of
guidelines.
How to ensure that trial data at the
individual-patient level can be pooled
for enhanced meta-analysis when
reviewing evidence for policy making
by WHO and other professional bodies
Data should be collected using standard
definitions, and use of data standards for
clinical trial is essential. Clinical trial data
should be made available for sharing so
as to conduct individual patient–level
data analyses. Such databases are used by
WHO and other recommending bodies
for policy development.
GRADE method should be well
understood by all stakeholders
As data quality improves,
recommendations based on lower-quality
data should be reexamined. A relevant
process to address this should be
established.
Abbreviations: GRADE, Grading of Recommendations Assessment, Development, and Evaluation; MDR, multidrug-resistant; TB, tuberculosis; WHO, World Health
Organization
https://doi.org/10.1371/journal.pmed.1002915.t003
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Conclusion
Given the recent enthusiasm for pursuing novel trial designs in TB therapeutics [37, 39], more
interactions will be needed between researchers responsible for designing the next generation
of TB trials, regulators, and policy makers. This will allow better harmonization across the
research pipeline and subsequent policies on access to TB medicines. Further, stakeholders,
including donors and funders, need to acknowledge that both explanatory and pragmatic trials
are needed to answer questions about efficacy and safety (explanatory) as well as expected
effectiveness in programmatic conditions (pragmatic). In all cases, endpoints should be spe-
cific to the purposes. Late-phase clinical trial outputs that serve the objective of registration of
a new TB drug or regimen can indeed meet the needs for development of public health guide-
lines, provided that data on long-term, patient-relevant, and population-relevant outcomes are
being collected. Additionally, public health factors such as feasibility, acceptability, resource
use, equity, and quality of life should be part of data collections, as these are necessary when
formulating public health recommendations. The existing dialogue between drug developers
and regulators should be expanded to policy makers under formal mechanisms of consulta-
tion, such as the one offered by WHO Task Forces [19]. More effective input from policy mak-
ers could greatly streamline and strengthen the value of TB clinical trial data in clinical
settings. Such interactions with policy makers can be invaluable at the design stages and would
result in better harmonization between the research pipeline and policies on access to TB med-
icines. The broad discussions that we propose would also ensure that secondary pooled analy-
ses performed by WHO (or other policy-recommending bodies) are reliable and that the risk
of conflicting interpretation and messaging provided by investigators and policy makers is
reduced and usefully contribute to the generation of reliable and relevant data for further pol-
icy guidance on the treatment of all forms of TB [2].
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